Olmesartan Medoxomil BP +Hydrochlorothiazide USP
Composition : Olmetic Plus : Olmesartan Medoxomil 20 mg + Hydrochlorothiazide 12.5 mgTablet.
Indication : Olmesartan Medoxomil is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Dosage and administration :
Olmetic Plus : A patient whose blood pressure is inadequately controlled by olmesartan or hydrochlorothiazide alone may be switched to one tablet (olmesaran medoxomil 20mg-hydrochlorothiazide 12.5mg) once daily.
Patients with Renal Impairment : The usual regimens of therapy with olmesartanhydrochlorothiazide may be followed provided the patient's creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so olmesartan-hydrochlorothiazide is not recommended. Patients with Hepatic Impairment : No dosage adjustment is necessary with hepatic impairment. Or, as directed by the registered physicians.
Use in pregnancy and lactation : Pregnancy Categories C (first trimester) and D (second and third trimesters). It is not known whether Olmesartan Medoxomil is excreted in human milk. Mothers must not breast-feed if they are taking Olmesartan Medoxomil. Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, this drug should be discontinued as soon as possible. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Packing : Olmetic Plus : 3 x 14's tablets in blister pack.